Royalty Pharma
RPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 99
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
356% more call options, than puts
Call options by funds: $81.6M | Put options by funds: $17.9M
25% more capital invested
Capital invested by funds: $9.86B [Q1] → $12.3B (+$2.45B) [Q2]
21% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 63
10% more repeat investments, than reductions
Existing positions increased: 170 | Existing positions reduced: 154
8.01% more ownership
Funds ownership: 73.08% [Q1] → 81.09% (+8.01%) [Q2]
2% more funds holding
Funds holding: 442 [Q1] → 450 (+8) [Q2]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Citigroup
Geoff Meacham
|
$42
|
Buy
Maintained
|
22 Jul 2025 |
|
Morgan Stanley
Terence Flynn
|
$54
|
Overweight
Maintained
|
10 Jul 2025 |
Financial journalist opinion
Based on 12 articles about RPRX published over the past 30 days
